# Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

> **NCT03100006** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Centre, Singapore** · enrollment: 13 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Oregovomab

## Key facts

- **NCT ID:** NCT03100006
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-22
- **Primary completion:** 2019-06-07
- **Final completion:** 2020-04-17
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The study had poor efficacy.
- **Last updated:** 2022-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100006, "Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03100006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*